SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date
of
earliest event reported):
May 3, 2007
CYTORI
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-32501
|
33-0827593
|
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer Identification Number)
|
3020
Callan Road, San Diego, California 92121
(Address
of principal executive offices, with zip code)
(858)
458-0900
(Registrant's
telephone number, including area code)
n/a
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
| o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
| o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
| o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR
240.13e-4(c))
|
Item
5.02 Departure
of Directors or Certain Officers; Election of Directors; Appointment
of Certain
Officers; Compensatory Arrangements of Certain Officers.
Marshall
G. Cox retired from our board of directors, effective May 3, 2007.
Mr. Cox is
being honored with recognition as Chairman Emeritus for his founding
efforts and
10 years of dedicated service as our Chairman of the Board.
Under
a
Consulting Agreement dated May 3, 2007, Mr. Cox will provide us with
up to 10
hours of consulting services per month through March 1, 2009. He will
receive
consulting fees of $5,000 per month. In addition, Mr. Cox agreed to
restrictions
on the number of shares of our common stock that he may sell over the
next 15
months. We also agreed to reimburse up to $5,000 of Mr. Cox’s attorneys fees in
connection with the Consulting Agreement.
Mr.
Cox
is the father-in-law of our Chief Executive Officer Christopher J.
Calhoun.
Incumbent
director Ronald D. Henriksen was appointed by the board to serve as
Interim
Chairman of the Board. Mr. Henriksen will be compensated at the rate
of an
additional $10,000 per year for such service.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| CYTORI THERAPEUTICS, INC. | |
| Date: May 4, 2007 | By: /s/ Marc H. Hedrick |
| Marc H. Hedrick | |
| President |
3